Adult non-cystic fibrosis bronchiectasis is characterised by airway luminal Th17 pathway activation

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Chen, Alice C H ^a   Martin, Megan L ^b   Lourie, Rohan ^a,c   Rogers, Geraint B ^d,e   Burr, Lucy D ^a,b   Hasnain, Sumaira Z ^a   Bowler, Simon D ^b   McGuckin, Michael A ^a   Serisier, David J ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b MATER ADULT HOSPITAL   (Australia)

^c MATER HOSPITAL   (Australia)

^d SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

^e FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; INTERLEUKIN DERIVATIVE;

ADULT; ARTICLE; BACTERIUM CULTURE; BRONCHIECTASIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FORCED EXPIRATORY VOLUME; GENE; GENE EXPRESSION; HAEMOPHILUS INFLUENZAE; HUMAN; IL 17A GENE; IL 1BETA GENE; IL 23 GENE; IL 8 GENE; LUNG INFECTION; LUNG LAVAGE; MALE; NEUTROPHIL; NON CYSTIC FIBROSIS BRONCHIECTASIS; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; PSEUDOMONAS INFECTION; TH17 CELL; ADOLESCENT; AGED; BRONCHOALVEOLAR LAVAGE FLUID; CASE CONTROL STUDY; CYTOLOGY; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGY; MIDDLE AGED; PATHOLOGY; PSEUDOMONAS AERUGINOSA; VERY ELDERLY;

HAEMOPHILUS INFLUENZAE; PSEUDOMONAS AERUGINOSA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRONCHIECTASIS; BRONCHOALVEOLAR LAVAGE FLUID; CASE-CONTROL STUDIES; FEMALE; HAEMOPHILUS INFLUENZAE; HUMANS; INTERLEUKINS; MALE; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; TH17 CELLS;

EID: 84926332225     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119325     Document Type: Article

References (29)

1. Tsang KW, Bilton D. Clinical challenges in managing bronchiectasis. Respirology 2009; 14:637-50. doi: 10.1111/j.1440-1843.2009.01569.x PMID: 19659645
2. Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and economic burden of bronchiectasis. Clin Pulm Med 2005; 12:205-9.
3. O'Brien C, Guest PJ, Hill SL, Stockley RA. Physiological and radiological characterization of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax 2000; 55:635-42. PMID: 10899238
4. Martinez-Garcia MA, de la Rosa Carrillo D, Soler-Cataluna JJ, Donat-Sanz Y, Serra PC, Lerma MA, et al. Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187:823-31. doi: 10.1164/rccm.201208-1518OC PMID: 23392438
5. Angrill J, Agusti C, De Celis R, Filella X, Rañó A, Elena M, et al. Bronchial inflammation and colonisation in patients with clinically stable bronchiectasis. Am J Respir Crit Care Med 2001; 164:1628-32. PMID: 11719301
6. Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, Hill AT. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-CF bronchiectasis. Am J Respir Crit Care Med 2012; 186:657-665. doi: 10.1164/rccm.201203-0487OC PMID: 22744718
7. Rogers GB, van der Gast CJ, Cuthbertson L, Thomson SK, Bruce KD, Martin ML, et al. Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition. Thorax 2013; 68:731-7. doi: 10.1136/thoraxjnl-2012-203105 PMID: 23564400
8. Cole PJ. Inflammation: a two-edged sword - the model of bronchiectasis. Eur J Respir Dis Suppl 1986; 147:6-15. PMID: 3533593
9. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009; 361:888-98. doi: 10.1056/NEJMra0707449 PMID: 19710487
10. Zheng L, Lam WK, Tipoe GL, Shum IH, Yan C, Leung R, et al. Overexpression of matrix metalloproteinase-8 and -9 in bronchiectatic airways in vivo. Eur Respir J 2002; 20:170-6. PMID: 12166566
11. Tan HL, Regamey N, Brown S, Bush A, Lloyd CM, Davies JC. The Th17 pathway in cystic fibrosis lung disease. Am J Respir Crit Care Med 2011; 184;252-258. doi: 10.1164/rccm.201102-0236OC PMID: 21474644
12. Tiringer K, Treis A, Fucik P, Gona M, Gruber S, Renner S, et al. A Th17- and Th2-skewed cytokine profile in cystic fibrosis lungs represents a potential risk factor for Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2013; 187:621-629. doi: 10.1164/rccm.201206-1150OC PMID: 23306544
13. Fouka E, Lamprianidou E, Arvanitidis K, Filidou E, Kolios G, Miltiades P, et al. Low-dose clarithromycin therapy modulates Th17 response in non-cystic fibrosis bronchiectasis patients. Lung 2014; 192: 849-55. doi: 10.1007/s00408-014-9619-0 PMID: 25016929
14. Serisier DJ, Martin ML, McGuckin MA, Lourie R, Chen AC, Brain B, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA 2013; 309:1260-1267. doi: 10.1001/jama.2013.2290 PMID: 23532242
15. Serisier DJ, Martin M. Long-term, low-dose erythromycin in subjects with frequent exacerbations. Respir Med 2011; 105:946-9. doi: 10.1016/j.rmed.2011.01.009 PMID: 21367595
16. Decraene A, Willems-Widyastuti A, Kasran A, Boeck K, Bullens DM, Dupont LJ. Elevated expression of both mRNA and protein levels of IL-17a in sputum of stable cystic fibrosis patients. Respir Res 2010; 11:177. doi: 10.1186/1465-9921-11-177 PMID: 21143945
17. McAllister F, Henry A, Kreindler JL, Dubin PJ, Ulrich L, Steele C, et al. Role of IL-17A, IL-17F, and the IL-17 receptor in regulating growth-related oncogene-alpha and granulocyte colony-stimulating factor in bronchial epithelium: implications for airway inflammation in cystic fibrosis. J Immunol 2005; 175;404-412. PMID: 15972674
18. Brodlie M, Corris PA, Lordan J, Ward C. Interleukin-17 and cystic fibrosis lung disease. Am J Respir Crit Care Med 2012; 185:108-9. PMID: 22210793
19. Tan HL, Davies J, Brown S, Bush A, Lloyd CM, Davies JC. Response to Brodlie et al. Am J Respir Crit Care Med 2012; 185:109-10.
20. Vanaudenaerde BM, Verleden SE, Vos R, De Vleeschauwer SI, Willems-Widyastuti A, Geenens R, et al. Innate and adaptive interleukin-17-producing lymphocytes in chronic inflammatory lung disorders. Am J Respir Crit Care Med 2011; 183:977-86. doi: 10.1164/rccm.201007-1196PP PMID: 21097694
21. Gaga M, Bentley AM, Humbert M, Barkans J, O'Brien F, Wathen CG, et al. Increases in CD4+ T lymphocytes, macrophages, neutrophils and interleukin 8 positive cells in the airways of patients with bronchiectasis. Thorax 1998; 53:685-691. PMID: 9828857
22. Zheng L, Shum H, Tipoe GL, Leung R, Lam WK, Ooi GC, et al. Macrophages, neutrophils and tumour necrosis factor-alpha expression in bronchiectatic airways in vivo. Respir Med 2001; 95:792-798. PMID: 11601743
23. Cua DJ, Tato CM. Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol 2010; 10: 479-89. doi: 10.1038/nri2800 PMID: 20559326
24. Tsai H-C, Velichko S, Hung L-Y, Wu R. IL-17a and Th17 cells in lung inflammation: an update on the role of Th17 cell differentiation and IL-17R signaling in host defense against infection. Clin Dev Immunol 2013; 2013:267971. doi: 10.1155/2013/267971 PMID: 23956759
25. Yang XO, Chang SH, Park H, Nurieva R, Shah B, Acero L, et al. Regulation of inflammatory responses by IL-17F. J Exp Med 2008; 205:1063-75. doi: 10.1084/jem.20071978 PMID: 18411338
26. Garraud K, Cleret A, Mathieu J, Fiole D, Gauthier Y, Quesnel-Hellmann A. Differential role of the interleukin-17 axis and neutrophils in resolution of inhalational anthrax. Infect Immun 2012; 80: 131-42. doi: 10.1128/IAI.05988-11 PMID: 22025514
27. Rogers GB, Zain MMH, Bruce KD, Burr LD, Chen AC, Rivett DW, et al. A novel microbiota stratification system predicts future exacerbations in bronchiectasis. Ann Am Thorac Soc 2014; 11:496-503. doi: 10.1513/AnnalsATS.201310-335OC PMID: 24592925
28. Rogers GB, Bruce KD, Burr L, Martin M, Serisier DJ. The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial. Lancet Respir Med 2014; 2: 988-96. doi: 10.1016/S2213-2600(14)70213-9 PMID: 25458200
29. Sutterwala FS, Mijares LA, Li Q, Ogura Y, Kazmierczak BI, Flavell RA. Immune recognition of Pseudomonas aeruginosa mediated by the IPAF/NRLC4 inflammasome. J Exp Med 2007; 204: 2235-45.